Emerging molecular markers of metastatic pheochromocytomas and paragangliomas
| Autor: | Anne-Paule Gimenez-Roqueplo, Judith Favier, Luis Jaime Castro-Vega, Charlotte Lussey-Lepoutre, Judith Goncalves |
|---|---|
| Přispěvatelé: | Paris-Centre de Recherche Cardiovasculaire (PARCC (UMR_S 970/ U970)), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Université Paris Descartes - Faculté de Médecine (UPD5 Médecine), Université Paris Descartes - Paris 5 (UPD5), Paris-Centre de Recherche Cardiovasculaire (PARCC - UMR-S U970), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), CCSD, Accord Elsevier, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP) |
| Rok vydání: | 2019 |
| Předmět: |
Oncology
medicine.medical_specialty Endocrinology Diabetes and Metabolism [SDV]Life Sciences [q-bio] Metastatic pheochromocytoma Adrenal Gland Neoplasms 030209 endocrinology & metabolism Pheochromocytoma Diagnostic tools Metastasis Paraganglioma 03 medical and health sciences 0302 clinical medicine Endocrinology Risk Factors Internal medicine Biomarkers Tumor Medicine Humans Genetic Predisposition to Disease Neoplasm Metastasis business.industry General Medicine medicine.disease Prognosis 3. Good health [SDV] Life Sciences [q-bio] 030220 oncology & carcinogenesis Risk stratification business |
| Zdroj: | Annales d'Endocrinologie Annales d'Endocrinologie, Elsevier Masson, 2019, 80, pp.159-162. ⟨10.1016/j.ando.2019.04.003⟩ |
| ISSN: | 2213-3941 0003-4266 |
| DOI: | 10.1016/j.ando.2019.04.003⟩ |
| Popis: | Metastatic pheochromocytoma/paraganglioma (PPGL) represents a major clinical challenge due to limitations in accurate diagnostic tools and effective treatments. Currently, patients classified at high-risk by means of clinical, biochemical and genetic criteria, require a lifelong monitoring, while it remains difficult to determine the metastatic potential of PPGL only on the basis of histopathological features. Thus, tumor molecular markers that improve the risk stratification of these patients are needed. In the past few years, we have witnessed an unprecedented molecular characterization of PPGL, which led to the emergence of promising candidate biomarkers predictive of metastatic behavior. Here, we briefly discuss these breakthroughs and provide some insights for the prospective implementation of molecular markers of metastatic PPGL in the clinical setting in years to come. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect